Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine
George V. Papatheodoridis, Evangelini Dimou, Konstantinos Dimakopoulos, Spilios Manolakopoulos, Irene Rapti, George Kitis, Dimitrios Tzourmakliotis, Emanuel Manesis, Stephanos J. Hadziyannis – 16 June 2005 – We determined the clinical outcome of hepatitis e antigen (HBeAg)‐negative chronic hepatitis B patients treated with long‐term nucleos(t)ide analog therapy starting with lamivudine. We evaluated 201 such patients treated for 3.8 ± 1.4 years and 2 historical similar cohorts: 1 treated with interferon‐alfa (n = 209) and 1 untreated (n = 195).